> Details

Thaçi, Diamant; Steinmeyer, Katrin; Ebelin, Marie-Eve; Scott, Graham; Kaufmann, Roland

Occlusive Treatment of Chronic Hand Dermatitis with Pimecrolimus Cream 1% Results in Low Systemic Exposure, Is Well Tolerated, Safe, and Effective

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Occlusive Treatment of Chronic Hand Dermatitis with Pimecrolimus Cream 1% Results in Low Systemic Exposure, Is Well Tolerated, Safe, and Effective
  • Contributor: Thaçi, Diamant; Steinmeyer, Katrin; Ebelin, Marie-Eve; Scott, Graham; Kaufmann, Roland
  • imprint: S. Karger AG, 2003
  • Published in: Dermatology
  • Language: English
  • DOI: 10.1159/000070939
  • ISSN: 1018-8665; 1421-9832
  • Keywords: Dermatology
  • Origination:
  • Footnote:
  • Description: <jats:p>&lt;i&gt;Background:&lt;/i&gt; Pimecrolimus cream 1% (Elidel&lt;sup&gt;®&lt;/sup&gt;, SDZ ASM 981) is a novel, non-steroid inflammatory cytokine inhibitor, effective in the treatment of atopic dermatitis. Here, we evaluate the treatment of chronic hand dermatitis with pimecrolimus cream 1%. &lt;i&gt;Objectives:&lt;/i&gt; To determine pimecrolimus blood concentrations, and evaluate the safety, tolerability and efficacy following application of pimecrolimus cream 1% to subjects with chronic hand dermatitis. &lt;i&gt;Method:&lt;/i&gt; In this open-label, multiple-topical-dose, non-controlled, pharmacokinetic study, pimecrolimus cream 1% was applied twice daily to dorsal and palmar areas (affected and unaffected) of both hands. Evening applications (except day 8) were immediately followed by overnight occlusion (≧6 h). Full pharmacokinetic profile (days 1, 8 and 22), trough concentrations (days 3 and 15), physical examinations, laboratory measurements and adverse events were recorded. Efficacy was assessed via Investigators’ Global Assessment (IGA), total key signs and symptoms and the subject’s overall self-assessment. &lt;i&gt;Results:&lt;/i&gt; Twelve patients completed the study. The majority of pimecrolimus blood concentrations (73.6%) remained below the limit of quantitation (0.1 ng/ml). The maximum concentration observed was 0.91 ng/ml and the maximum area under the concentration-time curve from 0–12 h post dose was 7.6 ng·h/ml. Treatment was well tolerated locally and systemically. No serious adverse events occurred; 4/13 subjects showed a total of 6 adverse events at the application site: burning (n = 4), and pruritus (n = 2). No clinically relevant or drug-related changes were observed. Clear efficacy of the treatment was shown by all 3 assessment methods. Disease state at day 22 had improved in 11 (85%) subjects compared with baseline (IGA). &lt;i&gt;Conclusion:&lt;/i&gt; Twice daily topical treatment of moderate to severe chronic hand dermatitis with pimecrolimus cream 1% results in low pimecrolimus blood levels, is well tolerated, safe, and effective.</jats:p>